Drug Profile
Paclitaxel oral - DAE HWA Pharmaceutical
Alternative Names: DHP-107; Liporaxel; RMX-3001Latest Information Update: 16 Sep 2022
Price :
$50
*
At a glance
- Originator DAE HWA Pharmaceutical
- Developer DAE HWA Pharmaceutical; HaiHe Biopharma
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Gastric cancer
- Phase III Breast cancer
- Phase I Solid tumours
Most Recent Events
- 14 Sep 2022 Phase-III clinical trials in Breast cancer in Eastern Europe, South Korea (PO) (HaiHe Biopharma pipeline, September 2022)
- 13 Sep 2022 Preregistration for Gastric cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO)
- 13 Sep 2022 National Medical Products Administration-Center for Drug Evaluation (NMPA-CDE) in China accepts MAA for paclitaxel oral solution for Gastric cancer (Second-line therapy or greater)